Thank you to all our Partner organisations:
BOEHRINGER INGELHEIM IN THE UK
We are Boehringer Ingelheim - a different kind of pharmaceutical company.
Family-owned. Purpose-led. Innovation-driven: We serve mankind by improving health for people and animals.
Making new and better medicines for humans and animals is at the heart of what we do. Our mission is to create breakthrough therapies that change lives. Established in 1885, we have always been independent and family-owned, meaning we have the freedom to pursue our purpose - identifying health challenges of the future, and targeting areas of need where we can do the most good.
By working collaboratively, we accelerate the delivery of medical breakthroughs to transform the lives of patients now, and for generations to come.
In the UK we do this through scientific innovation – taking on the biggest challenges in medicine. We invest in sustainable healthcare - planning for the long term alongside the NHS and our partners in the veterinary world. We support digital transformation by partnering with innovators to drive healthcare improvements.
We are committed to tackling the challenge of climate change and are a certified carbon neutral organisation. We serve local and global communities through our social impact programme and we support social entrepreneurs who find healthcare solutions for the most vulnerable.
More information can be found at www.boehringer-ingelheim.co.uk
PC-GB-102424 - Date of Preparation August 2020
Chiesi Limited is headquartered in Manchester and employs over 400 people. Based in Parma, Italy, Chiesi Farmaceutici is an international research-focused group with over 85 years’ experience in the pharmaceutical sector operating in 30 countries, employing around 6,000 people. To achieve its mission of improving people’s quality of life by acting responsibly towards society and the environment, Chiesi researches, develops and markets drugs in its three therapeutic areas: AIR (respiration, from new-born to adult populations), RARE (rare and ultra-rare diseases) and CARE (special care and consumer-facing self-care). Chiesi, since 2019, is the world’s largest B Corp certified pharmaceutical group.
Further information: www.chiesi.uk.com
At Insmed, our mission is to transform the lives of patients with serious and rare diseases. Our vision is to be a globally recognized leading biotech company that empowers great people to deliver, with a profound sense of urgency and compassion, life-altering therapies to small patient populations experiencing big health problems.
GSK is a science-led global healthcare company with a mission to help people do more, feel better and live longer. For more than 50 years, GSK has been a leader in respiratory, helping patients with respiratory disease better manage their condition. Working in collaboration with the scientific community, we remain at the cutting-edge of scientific research into innovative medicines with the aim of helping to treat patients’ symptoms and reduce the risk of their disease.
For further information please visit www.gsk.com.
Date of preparation: March 2019 PM-GB-RS-BRF-190009